Navigation Links
Bench to bassinet program seeks congenital heart disease treatments
Date:3/16/2010

What: To help speed the translation of scientific discoveries into usable treatments in congenital heart disease, the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health launched the Bench to Bassinet Program (http://www.benchtobassinet.net/). This program, which involves several major research institutions across the country, will be highlighted in the March 23 edition of the Journal of the American College of Cardiology. Congenital heart disease affects the lives of 40,000 newborns a year in the United States, and up to 2 million adults are living with congenital heart disease.

The Bench to Bassinet Program consists of three major research efforts. The two newest, highlighted in the journal article, are the Pediatric Cardiac Genomic Consortium and the Cardiovascular Development Consortium. The Bench to Bassinet Program also coordinates with the NHLBI-funded Pediatric Heart Network (http://www.pediatricheartnetwork.com/), a group of academic institutions in the United States and Canada conducting research to determine optimal therapies for children with congenital and acquired heart disease. New England Research Institutes serves as the coordinating center for the overall program.

Investigators in the Pediatric Cardiac Genomics Consortium will search the human genome for genetic defects that lead to heart problems. The participating research centers will study genetic data from hundreds of individuals born with congenital heart disease to uncover genes that may cause congenital heart disease, and how those genes influence the outcome of therapy. The institutes conducting this research are: The Children's Hospital Boston and the Brigham and Women's Hospital, Mass.; The Children's Hospital of Philadelphia, Pa. ; Columbia University Health Science, New York City; the Mount Sinai School of Medicine, New York City; and Yale University, New Haven, Conn.

Researchers still have many questions about the various complex pathways that lead to the creation of a healthy heart. Advances in technology and recent research findings make this an opportune time to launch an intensive collaboration designed to provide a comprehensive picture of the key steps in the development of healthy and abnormal hearts. Teams in the Cardiovascular Development Consortium will offer vital insights into heart development. The research institutes are: the J. David Gladstone Institutes, San Francisco, Calif.; Harvard University Medical School, Boston, Mass; the University of Pittsburgh, Pa.; and the University of Utah, Salt Lake City.

These two new programs, along with the Pediatric Heart Network, provide the framework to move fundamental knowledge rapidly into clinical practice, and to use insights from clinical practice to inform basic and genetic research.


'/>"/>

Contact: NHLBI Communications Office
nhlbi_news@nhlbi.nih.gov
301-496-4236
NIH/National Heart, Lung and Blood Institute
Source:Eurekalert

Related medicine news :

1. Indian Bollywood Masala Sets New Benchmarks in Blogspot World
2. Reportlinker Adds The Future of Respiratory Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
3. Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
4. Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
5. Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
6. Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
7. Reportlinker Adds Oncology Roadmap: Brand Spending Benchmarks and Market Forecast to 2013
8. Pitt part of $100 million NHLBI Bench to Bassinet effort in congenital heart disease
9. UHC Benchmarking Project Focuses on Patient- and Family-Centered Care in Academic Medical Centers
10. Integrated Benefits Institute Announces Availability of 2008 IBI Benchmarking Industry Reports
11. Experts Outline Challenges to Translational Research in the United States at a Capitol Hill Briefing, Emphasizing the Importance of Bringing Medical Innovation from Bench to Bedside
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a ... of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners ... October 11, 2017. , The annual award competition recognizes editorial and design excellence across ...
(Date:10/12/2017)... Wesley Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... Chapel is holding a treadmill relay – Miles by Moonlight to raise money for ... by donating $300 or more. , Teams will work together to keep their ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... first interactive health literacy software tool, and the Cancer Patient Education Network (CPEN), ... patient education, today announce a new strategic alliance. , As CPEN’s strategic ...
(Date:10/12/2017)... ... 12, 2017 , ... Vohra Chief Medical Officer Dr. Shark ... skilled nursing facility medical directors and other clinicians at various events in October. ... "At many of these conferences we get to educate other physicians, facility nurses, ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
(Date:9/22/2017)... , Sept. 22, 2017 AVACEN Medical ... device is now successfully helping those with the widespread ... Fibromyalgia diagnosed Amanda in Essex, England ... and washing my hair, experiencing no sleep at all, ... painful spasm… I cannot recommend [the AVACEN 100] enough, ...
Breaking Medicine Technology: